[1] |
CHEN Yaozhe, ZHAN Yunli, SONG Xingdong, ZHU Manyu, OU Xuemei, LI Chuyun.
48 Cases of Hematological Adverse Reactions Associated with Piperacillin Sodium and Tazobactam Sodium
[J]. Chinese Journal of Pharmacovigilance, 2025, 22(7): 794-798.
|
[2] |
XIE Ziyue, WANG Chengxiang, HU Yanpeng, LI Lei, CUI Herong.
Clinical Medications and Safety Analysis of Traditional Chinese Medicine for Post-Infection Cough
[J]. Chinese Journal of Pharmacovigilance, 2025, 22(5): 507-512.
|
[3] |
ZHANG Yunhui, CHEN Haoyun, ZHONG Luhua, FANG Caifu, HUANG Huanjun, GUO Chenchen, DONG Xinyi, SHI Feng, LIANG Weiting.
159 Cases of Adverse Reactions to Immune Checkpoint Inhibitors
[J]. Chinese Journal of Pharmacovigilance, 2025, 22(4): 442-446.
|
[4] |
WANG Han, WANG Cunxuan, LYU Xuehaiyue, ZHANG Lining, SUO Yusi, GU Zhi'en, WANG Ping, JIN Xuejing.
Chinese Patent Medicines for Preventing Myelosuppression in Adjuvant Treatment of Malignant Tumors: a Systematic Review and Network Meta-Analysis
[J]. Chinese Journal of Pharmacovigilance, 2025, 22(2): 169-176.
|
[5] |
YANG Shengxi, XU Juntong, TU Wenlian.
Research Progress in the Treatment of Advanced Non-Small Cell Lung Cancer with Aumonertinib
[J]. Chinese Journal of Pharmacovigilance, 2025, 22(2): 235-240.
|
[6] |
LU Zhenkai, YANG Dingquan, XIE Zhennian, WANG Lianxin, LI Yuanyuan, WANG Zhifei, CUI Xin, XIE Yanming.
Interpretation and insights from the “Guidelines for Pharmacovigilance of Topical Traditional Chinese Medicines in Clinical Applications”
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(9): 1029-1033.
|
[7] |
MENG kangkang, XIA Yukun.
Risks to safety of Ondansetron preparations
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(9): 1034-1038.
|
[8] |
LIN Lu, ZHAN Luchuan, LIU Xiaoqi, LIU Ju'e, WANG Laiyou, ZENG Ying, LAI Weihua.
Establish triggers for active monitoring of digoxin adverse events based on the China hospital pharmacovigilance system
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(9): 1039-1043.
|
[9] |
YAN Yan, LIU Naiyi, QIAO Ling, ZHANG Yi, YANG Chen.
One case of fulminant type 1 diabetes mellitus induced by allopurinol tablets hypersensitivity syndrome
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(9): 1068-1070.
|
[10] |
LU Jing, YU Shanshan, TONG Fei, LIN Zhuohui, SONG Luyao.
One case of severe constipation caused by dapagliflozin
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(9): 1071-1074.
|
[11] |
LI Fang, LONG Xiuying, BAI Na, WEI Jingxia.
One case of severe systemic rash caused by atorvastatin calcium tablets
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(8): 939-942.
|
[12] |
LIU Yan, AN Jing, JIAO Yongzhuo, LIANG Xuefeng, ZHANG Xiaoshu.
Simple febrile seizures within 30 days of vaccination with the measles, mumps and rubella combined attenuated live vaccine in U-12 children in the real world
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(7): 805-810.
|
[13] |
ZHAO Xuan, ZHENG Tingting, LI Xuemei, MAO Lu, GUO Jing, ZHANG Wei.
Adverse reaction reports of vancomycin in a hospital
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(7): 811-815.
|
[14] |
SHAO Bo, XU Lili, ZHU Lan, LIU Shuo, WAN Hao, HUANG Guangrui.
Risks of liver injury caused by Shiduqing preparations
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(6): 666-670.
|
[15] |
SUN Xuelin, DU Jiao, TAN Qin, HU Xin, ZHANG Yatong, ZHENG Li.
Analysis of post-marketing adverse reactions of ametinib
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(6): 683-686.
|